HRP20140486T1 - Postupci sinteze spojeva spirooksindola - Google Patents
Postupci sinteze spojeva spirooksindola Download PDFInfo
- Publication number
- HRP20140486T1 HRP20140486T1 HRP20140486AT HRP20140486T HRP20140486T1 HR P20140486 T1 HRP20140486 T1 HR P20140486T1 HR P20140486A T HRP20140486A T HR P20140486AT HR P20140486 T HRP20140486 T HR P20140486T HR P20140486 T1 HRP20140486 T1 HR P20140486T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- image
- obtaining
- Prior art date
Links
- 238000010189 synthetic method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 40
- 150000003839 salts Chemical class 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 14
- 238000006243 chemical reaction Methods 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 239000007818 Grignard reagent Substances 0.000 claims 2
- 238000006751 Mitsunobu reaction Methods 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 150000004795 grignard reagents Chemical class 0.000 claims 2
- 239000013067 intermediate product Substances 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Claims (8)
1. Postupak dobivanja spoja formule (I):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
naznačen time što se postupak sastoji u:
a) obradi spoja formule (7):
[image]
,
ili njegove farmaceutski prihvatljive soli, bazom u uvjetima pogodnim za dobivanje spoja formule (8):
[image]
,
ili njegove farmaceutski prihvatljive soli; i
b) obradi spoja formule (8):
[image]
,
ili njegove farmaceutski prihvatljive soli, spojem formule (9):
[image]
,
ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (I),
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese.
2. Postupak u skladu s patentnim zahtjevom 1, koji se dodatno sastoji u dobivanju spoja formule (7), naznačen time što se postupak sastoji u obradi spoja formule (6):
[image]
,
ili njegove farmaceutski prihvatljive soli, u standardnim uvjetima za Mitsunobuovu reakciju, kako bi se dobilo spoj formule (7),
ili njegovu farmaceutski prihvatljivu sol.
3. Postupak u skladu s patentnim zahtjevom 2, koji se dodatno sastoji u dobivanju spoja formule (6), naznačen time što se postupak sastoji u obradi spoja formule (5):
[image]
,
ili njegove farmaceutski prihvatljive sol, aldehidom u uvjetima pogodnim za dobivanje spoja formule (6),
ili njegove farmaceutski prihvatljive soli.
4. Postupak u skladu s patentnim zahtjevom 3, koji se dodatno sastoji u dobivanju spoja formule (5), naznačen time što se postupak sastoji u obradi spoja formule (4):
[image]
,
ili njegove farmaceutski prihvatljive soli, u uvjetima pogodnim za dobivanje spoja formule (5),
ili njegove farmaceutski prihvatljive soli.
5. Postupak u skladu s patentnim zahtjevom 4, koji se dodatno sastoji u dobivanju spoja formule (4), naznačen time što se postupak sastoji u:
a) reakciji spoja formule (2):
[image]
,
ili njegove farmaceutski prihvatljive soli, s Grignardovim reagensom formule (3):
[image]
u uvjetima pogodnim za dobivanje međuprodukta; i
b) reakciji međuprodukta iz a) sa spojem formule (1):
[image]
ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (4),
ili njegove farmaceutski prihvatljive soli.
6. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u razdvajanju spoja formule (I), ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-S):
[image]
,
ili njegove farmaceutski prihvatljive sol, i spoja formule (I-R):
[image]
,
ili njegove farmaceutski prihvatljive soli.
7. Postupak dobivanja spoja formule (I):
[image]
,
ili njegove farmaceutski prihvatljive sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, naznačen time što se postupak sastoji u:
a) reakciji spoja formule (2):
[image]
,
ili njegove farmaceutski prihvatljive soli, s Grignardovim reagensom formule (3):
[image]
u uvjetima pogodnim za dobivanje međuprodukta; i
b) reakciji međuprodukta iz a) sa spojem formule (1):
[image]
,
ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (4):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
c) obradi spoja formule (4), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, u uvjetima pogodnim za dobivanje spoja formule (5):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
d) obradi spoja formule (5), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, aldehidom u uvjetima pogodnim za dobivanje spoja formule (6):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
e) obradi spoja formule (6), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, u standardnim uvjetima za Mitsunobuovu reakciju, kako bi se dobilo spoj formule (7):
[image]
,
ili njegovu farmaceutski prihvatljivu sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
f) obradi spoja formule (7), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, bazom u uvjetima pogodnim za dobivanje spoja formule (8):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
g) obradi spoja formule (8):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, spojem formule (9):
[image]
,
ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (I),
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese.
8. Postupak u skladu s patentnim zahjevom 7, naznačen time što se dodatno sastoji u razdvajanju spoja formule (I), ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-S):
[image]
,
ili njegove farmaceutski prihvatljive soli, i spoja formule (I-R):
[image]
,
ili njegove farmaceutski prihvatljive soli.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25133509P | 2009-10-14 | 2009-10-14 | |
PCT/US2010/052704 WO2011047174A1 (en) | 2009-10-14 | 2010-10-14 | Synthetic methods for spiro-oxindole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140486T1 true HRP20140486T1 (hr) | 2014-07-04 |
Family
ID=43733239
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120368AA HRP20120368A2 (hr) | 2009-10-14 | 2012-04-27 | Postupci sinteze spiro-oksindolskih spojeva |
HRP20140486AT HRP20140486T1 (hr) | 2009-10-14 | 2014-05-29 | Postupci sinteze spojeva spirooksindola |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120368AA HRP20120368A2 (hr) | 2009-10-14 | 2012-04-27 | Postupci sinteze spiro-oksindolskih spojeva |
Country Status (23)
Country | Link |
---|---|
US (4) | US8445696B2 (hr) |
EP (2) | EP2733145A1 (hr) |
JP (3) | JP5752136B2 (hr) |
KR (1) | KR20120099429A (hr) |
CN (1) | CN102753556B (hr) |
AU (2) | AU2010306768B2 (hr) |
BR (1) | BR112012008993A2 (hr) |
CA (1) | CA2777543A1 (hr) |
CL (3) | CL2012000953A1 (hr) |
CO (1) | CO6531444A2 (hr) |
EC (1) | ECSP12011815A (hr) |
ES (1) | ES2467166T3 (hr) |
HK (2) | HK1174908A1 (hr) |
HR (2) | HRP20120368A2 (hr) |
MA (1) | MA33730B1 (hr) |
MX (1) | MX2012004373A (hr) |
MY (2) | MY165579A (hr) |
NZ (3) | NZ712378A (hr) |
PE (2) | PE20121350A1 (hr) |
RU (2) | RU2015103694A (hr) |
TN (1) | TN2012000171A1 (hr) |
WO (1) | WO2011047174A1 (hr) |
ZA (1) | ZA201202703B (hr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
TW200833695A (en) | 2006-10-12 | 2008-08-16 | Xenon Pharmaceuticals Inc | Use of spiro-oxindole compounds as therapeutic agents |
EP2076514A1 (en) * | 2006-10-12 | 2009-07-08 | Xenon Pharmaceuticals Inc. | Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
CN105175433A (zh) | 2008-10-17 | 2015-12-23 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
AU2010306768B2 (en) | 2009-10-14 | 2016-08-04 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
PE20121699A1 (es) | 2010-02-26 | 2012-12-22 | Xenon Pharmaceuticals Inc | Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica |
GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
AU2013246485A1 (en) * | 2012-04-12 | 2014-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
CN103724340A (zh) * | 2012-10-15 | 2014-04-16 | 南京大学 | 一类具有苯并含氧杂环结构的噻唑类衍生物及其制法 |
CN104326922B (zh) * | 2014-11-03 | 2016-08-17 | 成都百裕制药股份有限公司 | 替格瑞洛中间体(1r,2s)-2-(2,3-二氟苯基)环丙胺的制备方法 |
WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
CN105801556A (zh) * | 2014-12-31 | 2016-07-27 | 上海药谷药业有限公司 | 一种2,3-二氢-1,4-苯并二烷-6-羧酸化合物的制备方法 |
US9682033B2 (en) | 2015-02-05 | 2017-06-20 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
BR112018012327A2 (pt) | 2015-12-18 | 2018-12-04 | Merck Sharp & Dohme | compostos de diamina-arilsulfonamida substituídos com hidroxialquilamina e hidroxicicloalquilamina com atividade seletiva em canais de sódio ativados por voltagem |
WO2017218920A1 (en) | 2016-06-16 | 2017-12-21 | Teva Pharmaceuticals International Gmbh | Asymmetric synthesis of funapide |
AU2017283651B2 (en) * | 2016-06-16 | 2021-03-25 | Xenon Pharmaceuticals, Inc. | Solid state forms of spiro-oxindole compounds |
US11306100B2 (en) | 2017-03-10 | 2022-04-19 | Council Of Scientific & Industrial Research | Spirooxindole compounds as GSK3B inhibitors and process for preparation thereof |
MX2023005983A (es) | 2020-11-23 | 2023-08-15 | Enanta Pharm Inc | Nuevos agentes antivirales derivados de la espiropirrolidina. |
US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
WO2023177854A1 (en) * | 2022-03-18 | 2023-09-21 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of substituted spirooxindole derivatives |
CN115353499B (zh) * | 2022-10-21 | 2023-02-28 | 南京远淑医药科技有限公司 | 一种2-卤甲基-5-三氟甲基呋喃的合成方法 |
US11840545B1 (en) | 2023-07-14 | 2023-12-12 | King Faisal University | Spirooxindole-copper complex as novel efficient anticorrosion agent for C-steel |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3189617A (en) * | 1961-02-03 | 1965-06-15 | Sterling Drug Inc | 1-aryloxindoles and their preparation |
DE1956237A1 (de) | 1969-11-08 | 1971-05-13 | Basf Ag | Spiro-pyrrolizidon-oxindole |
DE2113343A1 (de) | 1971-03-19 | 1972-09-21 | Thiemann Chem Pharm Fab | Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung |
US3723459A (en) * | 1971-04-23 | 1973-03-27 | Mc Neil Labor Inc | 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
CH577461A5 (hr) * | 1975-08-13 | 1976-07-15 | Robins Co Inc A H | |
US4670566A (en) * | 1979-07-12 | 1987-06-02 | A. H. Robins Company, Incorporated | 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones |
US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4440785A (en) * | 1980-10-30 | 1984-04-03 | A. H. Robins Company, Inc. | Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation |
US4438130A (en) * | 1981-11-12 | 1984-03-20 | The Upjohn Company | Analgesic 1-oxa-, aza- and thia-spirocyclic compounds |
JPS60142984A (ja) | 1983-12-28 | 1985-07-29 | Kyorin Pharmaceut Co Ltd | 新規なスピロピロリジン−2,5−ジオン誘導体およびその製造法 |
US4569942A (en) | 1984-05-04 | 1986-02-11 | Pfizer Inc. | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents |
JPS6130554A (ja) * | 1984-07-23 | 1986-02-12 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤 |
US4690943A (en) | 1984-09-19 | 1987-09-01 | Pfizer Inc. | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds |
US4721721A (en) | 1984-12-18 | 1988-01-26 | Rorer Pharmaceutical Corporation | 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses |
DE3608088C2 (de) * | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
IL87116A (en) * | 1987-07-17 | 1993-03-15 | Schering Ag | 9-halogen-(z)-prostaglandin derivatives and pharmaceutical compositions containing the same |
US5182289A (en) * | 1988-06-14 | 1993-01-26 | Schering Corporation | Heterobicyclic compounds having antiinflammatory activity |
DK0429685T3 (da) | 1989-07-25 | 1997-12-15 | Taiho Pharmaceutical Co Ltd | Oxoindolderivat |
DE3932953A1 (de) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5023265A (en) * | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
US5484778C1 (en) | 1990-07-17 | 2001-05-08 | Univ Cleveland Hospitals | Phthalocynine photosensitizers for photodynamic therapy and methods for their use |
EP0558521A1 (en) | 1990-11-22 | 1993-09-08 | Janssen Pharmaceutica N.V. | Isonicotinic acid derivatives and related spiro compounds with herbicidal action |
US5116854A (en) * | 1991-06-28 | 1992-05-26 | Pfizer Inc. | Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles |
US5849780A (en) * | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
US5663431A (en) * | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
US5686624A (en) * | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
JPH08503450A (ja) | 1992-08-06 | 1996-04-16 | ワーナー−ランバート・コンパニー | 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する2−チオインドール(セレノインドール)および関連ジスルフィド(セレニド) |
US5278162A (en) * | 1992-09-18 | 1994-01-11 | The Du Pont Merck Pharmaceutical Company | 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man |
US5296478A (en) * | 1992-10-07 | 1994-03-22 | The Dupont Merck Pharmaceutical Co. | 1-substituted oxindoles as cognition enhancers |
US5776936A (en) * | 1992-11-13 | 1998-07-07 | Pharmacia & Upjohn Company | Marcfortine/paraherquamide derivatives useful as antiparasitic agents |
DE4242451A1 (de) * | 1992-12-16 | 1994-06-23 | Basf Ag | Verfahren zur Herstellung von 5-Ringheterocyclen |
US5298522A (en) | 1993-01-22 | 1994-03-29 | Pfizer Inc. | 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
FR2708606B1 (fr) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
US5502072A (en) | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
AT400950B (de) * | 1994-02-04 | 1996-04-25 | Immodal Pharmaka Gmbh | Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen |
AU2310895A (en) * | 1994-04-07 | 1995-10-30 | Cemaf | Novel spiro{indole-pyrrolidine} derivatives as melatoninergic agonists, method for preparing same and use thereofas a drug |
US5618819A (en) | 1994-07-07 | 1997-04-08 | Adir Et Compagnie | 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds |
FR2722195B1 (fr) | 1994-07-07 | 1996-08-23 | Adir | Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CA2208244A1 (en) | 1994-12-22 | 1996-06-27 | Laramie Mary Gaster | Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
CA2235686C (en) | 1995-10-24 | 2007-06-26 | Sanofi | Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them |
HUP9600855A3 (en) | 1996-04-03 | 1998-04-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tenidap |
JPH1095766A (ja) | 1996-09-19 | 1998-04-14 | Sanwa Kagaku Kenkyusho Co Ltd | アセトアミド誘導体、及びその用途 |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
EP0989856B1 (de) * | 1997-01-20 | 2010-05-12 | IMMODAL PHARMAKA GESELLSCHAFT m.b.H. | Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung |
NO317155B1 (no) * | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
EP1008588B1 (en) * | 1997-02-10 | 2003-04-16 | Ono Pharmaceutical Co., Ltd. | 11,15-o-dialkylprostaglandin e derivatives, process for producing the same, and drugs containing the same as the active ingredient |
AU741482B2 (en) | 1997-05-07 | 2001-11-29 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
KR20010033538A (ko) * | 1997-12-25 | 2001-04-25 | 오노 야꾸힝 고교 가부시키가이샤 | ω-시클로알킬-프로스타글란딘 E2 유도체 |
JP4087938B2 (ja) * | 1998-02-04 | 2008-05-21 | 高砂香料工業株式会社 | ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物 |
PT1087934E (pt) | 1998-04-01 | 2004-07-30 | Cardiome Pharma Corp | Compostos de eter de aminociclo-hexilo e as suas utilizacoes |
US20040038970A1 (en) * | 1998-06-12 | 2004-02-26 | Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. | Beta-carboline compounds |
US6235780B1 (en) * | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
AU5227999A (en) | 1998-07-27 | 2000-02-21 | Abbott Laboratories | Substituted oxazolines as antiproliferative agents |
SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
EP1183033B1 (en) | 1999-05-21 | 2006-03-01 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
WO2001006984A2 (en) * | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
ES2218191T3 (es) | 1999-07-21 | 2004-11-16 | Astrazeneca Ab | Nuevos compuestos. |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
DE1252330T1 (de) | 1999-11-26 | 2003-11-27 | Univ Montreal Mcgill | Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie |
FR2807038B1 (fr) | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
US20020045566A1 (en) | 2000-10-13 | 2002-04-18 | Gribkoff Valentin K. | Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
US6825220B2 (en) | 2000-11-10 | 2004-11-30 | Eli Lilly And Company | 3-Substituted oxindole β 3 agonists |
US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
US20030078278A1 (en) | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
WO2003016276A2 (en) * | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | 3-substituted oxindole beta-3 agonists |
EP1451160B1 (en) | 2001-11-01 | 2010-01-13 | Icagen, Inc. | Pyrazole-amides for use in the treatment of pain |
WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
ES2242890T3 (es) * | 2001-11-20 | 2005-11-16 | Eli Lilly And Company | Agonistas beta 3 de oxindol 3-sustituido. |
SE0104341D0 (sv) * | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
WO2003064425A1 (en) | 2002-01-28 | 2003-08-07 | Pfizer Japan Inc. | N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
US7250442B2 (en) | 2002-03-15 | 2007-07-31 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
BR0312092A (pt) | 2002-06-25 | 2005-03-22 | Wyeth Corp | Uso de derivados de tio-oxindol no tratamento de distúrbios da pele |
RU2005101635A (ru) | 2002-06-25 | 2005-08-10 | Уайт (Us) | Применение производных тиооксиндола в терапии гормонозависимых состояний |
US7256218B2 (en) | 2002-11-22 | 2007-08-14 | Jacobus Pharmaceutical Company, Inc. | Biguanide and dihydrotriazine derivatives |
KR20130066701A (ko) | 2003-02-24 | 2013-06-20 | 미쓰비시 타나베 파마 코퍼레이션 | 테나토프라졸의 거울상 이성질체 및 치료를 위한 그 용도 |
BRPI0410222A (pt) * | 2003-05-16 | 2006-05-09 | Pfizer Prod Inc | tratamento de distúrbios bipolares e sintomas associados |
BRPI0410419A (pt) * | 2003-05-16 | 2006-05-30 | Pfizer Prod Inc | tratamento para a ansiedade com ziprasidona |
MXPA05012391A (es) * | 2003-05-16 | 2006-02-02 | Pfizer Prod Inc | Tratamiento de trastornos psicoticos y depresivos. |
CA2625837A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Method for enhancing cognition using ziprasidone |
BRPI0412348A (pt) | 2003-07-30 | 2006-09-05 | Xenon Pharmaceuticals Inc | derivados de piperazina e seu uso como agentes terapêuticos |
DE10337184A1 (de) * | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
WO2005016913A1 (en) | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
WO2005035498A1 (ja) | 2003-10-08 | 2005-04-21 | Dainippon Sumitomo Pharma Co., Ltd. | 含窒素二環性化合物の摂食調節剤としての用途 |
EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
US7507760B2 (en) | 2004-01-22 | 2009-03-24 | Neuromed Pharmaceuticals Ltd. | N-type calcium channel blockers |
GB0406867D0 (en) | 2004-03-26 | 2004-04-28 | F2G Ltd | Antifungal agents |
US20080280873A1 (en) | 2004-03-29 | 2008-11-13 | Jun Liang | Biaryl Substituted Pyrazinones as Sodium Channel Blockers |
BRPI0509307A (pt) | 2004-03-29 | 2007-09-04 | Pfizer | compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1 |
GT200500063A (es) | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
US8211883B2 (en) | 2004-04-01 | 2012-07-03 | Case Western Reserve University | Topical delivery of phthalocyanines |
JP2007532496A (ja) | 2004-04-08 | 2007-11-15 | トポターゲット・アクティーゼルスカブ | ジフェニルオキソ−インドール−2−オン化合物および癌の処置におけるそれらの使用 |
BRPI0510260A (pt) | 2004-04-27 | 2007-10-23 | Wyeth Corp | método para purificar um composto, e, kit farmacêutico |
WO2005105753A2 (en) | 2004-05-05 | 2005-11-10 | Unibioscreen S.A. | Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom |
CN1950341A (zh) * | 2004-05-05 | 2007-04-18 | 优尼拜尔斯金股份有限公司 | 用于治疗癌症的萘二甲酰亚胺衍生物 |
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
WO2005111024A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1758882A4 (en) | 2004-06-24 | 2008-01-23 | Incyte Corp | AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS |
GT200500186A (es) | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
GT200500183A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
JP4677323B2 (ja) | 2004-11-01 | 2011-04-27 | キヤノン株式会社 | 画像処理装置及び画像処理方法 |
WO2006055752A2 (en) | 2004-11-18 | 2006-05-26 | Incyte Corporation | INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME |
DE102005007694A1 (de) | 2005-02-18 | 2006-09-21 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
BRPI0609172A2 (pt) | 2005-02-22 | 2010-02-23 | Univ Michigan | inibidores de pequenas moléculas de mdm2 e usos destes |
MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
AR053713A1 (es) * | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
MX2007013450A (es) * | 2005-04-29 | 2008-01-21 | Wyeth Corp | Procedimniento de preparacion de oxindoles y tio-oxindoles 3,3-disustituidos. |
EP1888581A2 (en) * | 2005-05-16 | 2008-02-20 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
CA2620034C (en) | 2005-09-01 | 2013-10-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
AU2007258675A1 (en) | 2006-06-09 | 2007-12-21 | Merck Sharp & Dohme Corp. | Benzazepinones as sodium channel blockers |
EP2076514A1 (en) | 2006-10-12 | 2009-07-08 | Xenon Pharmaceuticals Inc. | Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
WO2008046084A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
TW200833695A (en) * | 2006-10-12 | 2008-08-16 | Xenon Pharmaceuticals Inc | Use of spiro-oxindole compounds as therapeutic agents |
WO2008046082A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
WO2008046046A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
AR063277A1 (es) | 2006-10-12 | 2009-01-14 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y usos como agentes terapeuticos |
WO2008046087A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
GB0704846D0 (en) | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
EP3357904B1 (en) | 2007-05-29 | 2022-07-06 | Precigen, Inc. | Chiral diachylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
CA2920996A1 (en) * | 2007-10-19 | 2009-04-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
CN102056920A (zh) * | 2008-06-11 | 2011-05-11 | 埃科特莱茵药品有限公司 | 用作食欲素受体拮抗剂的四唑化合物 |
US20100040187A1 (en) | 2008-08-12 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Heat pipe nuclear fission deflagration wave reactor cooling |
CN105175433A (zh) | 2008-10-17 | 2015-12-23 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
US8101647B2 (en) * | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
WO2010053998A1 (en) | 2008-11-05 | 2010-05-14 | Xenon Pharmaceuticals, Inc. | Spiro-condensed indole derivatives as sodium channel inhibitors |
US20110269788A1 (en) * | 2008-12-29 | 2011-11-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole-derivatives as sodium channel blockers |
WO2010132352A2 (en) | 2009-05-11 | 2010-11-18 | Xenon Pharmaceuticals Inc. | Spiro compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
US20110086899A1 (en) | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
AU2010306768B2 (en) | 2009-10-14 | 2016-08-04 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
PE20121699A1 (es) | 2010-02-26 | 2012-12-22 | Xenon Pharmaceuticals Inc | Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica |
AU2013246485A1 (en) | 2012-04-12 | 2014-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
-
2010
- 2010-10-14 AU AU2010306768A patent/AU2010306768B2/en not_active Ceased
- 2010-10-14 MY MYPI2012001670A patent/MY165579A/en unknown
- 2010-10-14 RU RU2015103694/04A patent/RU2015103694A/ru not_active Application Discontinuation
- 2010-10-14 BR BR112012008993A patent/BR112012008993A2/pt not_active Application Discontinuation
- 2010-10-14 NZ NZ712378A patent/NZ712378A/en not_active IP Right Cessation
- 2010-10-14 RU RU2012119550/04A patent/RU2544852C2/ru not_active IP Right Cessation
- 2010-10-14 JP JP2012534362A patent/JP5752136B2/ja not_active Expired - Fee Related
- 2010-10-14 KR KR1020127012050A patent/KR20120099429A/ko not_active Application Discontinuation
- 2010-10-14 NZ NZ622072A patent/NZ622072A/en not_active IP Right Cessation
- 2010-10-14 EP EP14000519.0A patent/EP2733145A1/en not_active Withdrawn
- 2010-10-14 PE PE2012000480A patent/PE20121350A1/es not_active Application Discontinuation
- 2010-10-14 MX MX2012004373A patent/MX2012004373A/es active IP Right Grant
- 2010-10-14 WO PCT/US2010/052704 patent/WO2011047174A1/en active Application Filing
- 2010-10-14 EP EP10771606.0A patent/EP2488531B1/en active Active
- 2010-10-14 US US12/904,880 patent/US8445696B2/en active Active
- 2010-10-14 PE PE2016001459A patent/PE20170202A1/es not_active Application Discontinuation
- 2010-10-14 CN CN201080056856.0A patent/CN102753556B/zh not_active Expired - Fee Related
- 2010-10-14 NZ NZ599334A patent/NZ599334A/en not_active IP Right Cessation
- 2010-10-14 ES ES10771606.0T patent/ES2467166T3/es active Active
- 2010-10-14 MY MYPI2016001835A patent/MY179342A/en unknown
- 2010-10-14 CA CA2777543A patent/CA2777543A1/en not_active Abandoned
-
2012
- 2012-04-13 TN TNP2012000171A patent/TN2012000171A1/en unknown
- 2012-04-13 ZA ZA2012/02703A patent/ZA201202703B/en unknown
- 2012-04-13 CL CL2012000953A patent/CL2012000953A1/es unknown
- 2012-04-13 CO CO12061009A patent/CO6531444A2/es unknown
- 2012-04-18 EC ECSP12011815 patent/ECSP12011815A/es unknown
- 2012-04-27 HR HRP20120368AA patent/HRP20120368A2/hr not_active Application Discontinuation
- 2012-05-07 MA MA34841A patent/MA33730B1/fr unknown
- 2012-09-14 US US13/620,391 patent/US8742109B2/en not_active Expired - Fee Related
-
2013
- 2013-02-15 HK HK13101970.7A patent/HK1174908A1/xx not_active IP Right Cessation
- 2013-12-18 CL CL2013003633A patent/CL2013003633A1/es unknown
-
2014
- 2014-05-07 US US14/272,297 patent/US9260446B2/en not_active Expired - Fee Related
- 2014-05-29 HR HRP20140486AT patent/HRP20140486T1/hr unknown
- 2014-10-22 HK HK14110536A patent/HK1197233A1/xx unknown
-
2015
- 2015-03-02 JP JP2015039888A patent/JP5951825B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-06 US US14/989,600 patent/US9695185B2/en not_active Expired - Fee Related
- 2016-04-15 JP JP2016081755A patent/JP2016130260A/ja active Pending
- 2016-07-06 CL CL2016001732A patent/CL2016001732A1/es unknown
- 2016-07-27 AU AU2016208347A patent/AU2016208347A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140486T1 (hr) | Postupci sinteze spojeva spirooksindola | |
JP2010043124A5 (hr) | ||
FR2998297B1 (fr) | Procede de preparation de sel d'imides contenant un groupement fluorosulfonyle | |
FR2956867B1 (fr) | Procede de preparation d'un echantillon d'hemoculture contenant des microorganismes | |
EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
IN2014KN00943A (hr) | ||
MX368042B (es) | COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA RELACIONADA CON ATAXIA TELANGIECTASIA MUTADA Y Rad3 (ATR). | |
PT3710437T (pt) | Separação enantiomérica de nicotina racémica por adição de um enantiómero de ácido tartárico o,o'-disubstituído de baixa pureza ótica | |
EP2750789A4 (en) | SPOX OXIDIZATION PROCESS FOR PREPARING 2,5-FURANDIC ACETIC ACID FROM HYDROXYMETHYL FURFURAL | |
EP2484673A3 (en) | A process for the resolution of (R,S)-nicotine | |
MA40544B1 (fr) | Procédé de production d'un carbonate lié, article moulé sous pression | |
MX336925B (es) | Procedimiento para elaborar acido lactico. | |
FR2958291B1 (fr) | Procede de preparation de derives d'amino-benzofurane | |
MX2018010199A (es) | Proceso para la separacion de enantiomeros de derivados de piperazina. | |
FR2997266B1 (fr) | Procede de traitement sous hautes pressions de lait maternel | |
HRP20200437T1 (hr) | Proces za pripremu enantiomerom obogaćenog 3-aminopiperidina | |
FR2934160B1 (fr) | Procede de preparation d'un extrait lipophile de vigne. | |
WO2012093411A3 (en) | Process for the preparation of r-(-)-3- (carbamoylmethyl)-5-methylhexanoic acid and the intermediates | |
FR3033702B1 (fr) | Procede de preparation d'un extrait de plante avec un compose amphiphile non ionique comme adjuvant d'extraction en milieu aqueux | |
FR3053336B1 (fr) | Procede de preparation de l'acide 2,5-furane dicarboxylique (fdca) a partir de derives de pentoses | |
FR2957076B1 (fr) | Procede de production d'acide pyrrolidonecarboxylique ou d'un sel de celui-ci, acide pyrrolidonecarboxylique ainsi obtenu et cosmetique le contenant | |
FR2976284B1 (fr) | Nouveaux co-cristaux d'agomelatine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
EP3272734A8 (en) | Ahu377 crystal form, preparation method and use thereof | |
FR2947933B1 (fr) | Procede de traitement de donnees permettant le filtrage d'artefacts, adapte notamment a l'electroencephalographie | |
DE602007010926D1 (de) | Neues verfahren zur herstellung von ammoniumsalzen von esomeprazol |